Vijay Kanakadandi, MD
San Diego—Clinical studies are keeping alive the potential for commercial development of drugs to provide meaningful acid control beyond proton pump inhibitors (PPIs), according to data presented at the 2016 Digestive Disease Week.
In one set of new data, secretol, a combination of antacid medications, was found effective for treating the acid pocket in patients with Barrett’s esophagus (abstract 1087). In the other, clinical data generated by a study of the